Corporate digest

Trendlines Group

CATALIST-LISTED Trendlines Group, the Israel-based group which focuses on early-stage, high growth innovation-based medical and agricultural technologies, has signed a definitive agreement to sell its BioSight Ltd shares to Arkin Bio Ventures Limited Partnership that will bring it pre-tax proceeds of about US$1.3 million.

"BioSight developed a technology and pipeline of cancer drugs that target and release therapeutic drugs inside cancer cells to reduce systemic toxicity associated with conventional chemotherapy treatments," Trendlines said.